ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
May 27, 2020 11:41 JST
Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences' COVID-19 Neutralizing Antibodies
- CB6 demonstrated prophylactic and treatment effects in rhesus monkeys
- Clinical testing expected to begin in second quarter in collaboration with Eli Lilly and Company
SHANGHAI, CHINA, May 27, 2020 - (ACN Newswire) - Junshi Biosciences (HKEX: 1877) a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the publication of research results from the company's efforts to generate therapeutic COVID-19 neutralizing antibodies. The paper, titled "A human neutralizing MAb targeting the receptor binding site of SARS-CoV-2" (Shi et al. Nature), was published today in the journal Nature. Junshi and partner Eli Lilly and Company (NYSE: LLY) intend to file an IND and initiate clinical trials in the U.S. and China in the second quarter of 2020.
The article reports the identification and characterization of two specific human monoclonal antibodies (CA1 and CB6) isolated from a recovered COVID-19 patient. While both antibodies demonstrated substantial neutralization activity in vitro against SARS-CoV-2, CB6 exhibited superior neutralizing activities. CB6 reduced virus levels by about 3 logs in rhesus monkeys when administered one day after infection. When given one day before viral challenge, CB6 was able to keep viral load at no more than 103 RNA copies/ml, demonstrating strong prophylactic protection. Structural studies showed that CB6 recognizes epitopes in SARS-CoV-2 receptor binding domain that overlap with angiotensin converting enzyme 2 (ACE2)-binding sites, thereby directly obstructing virus/receptor interactions. The Fc portion of CB6 was modified to lower the risk of Fc mediated acute lung injury.
"We have successfully leveraged the Company's years of expertise with our fully integrated R&D antibody technology platform, conducting multiple parallel development tracks of candidate antibodies that were subsequently tested in vivo infection model by the Institute of Microbiology, Chinese Academy of Sciences," said Hui Feng, Ph.D., Junshi Biosciences' Chief Operating Officer. "One of these candidates, described in the Nature paper, demonstrated strong neutralizing activity against COVID-19. We expect to file an IND for this candidate in the second quarter in collaboration with our partner, Lilly. As part of our effort to contribute in the fight against this global pandemic, our Company has increased its research and development efforts, leveraging our strengths in the field of antibody discovery."
"Lilly is proud to have partnered with Junshi Biosciences to develop CB6 as a potential treatment for COVID-19. The fact that CB6 can protect rhesus monkeys from COVID-19 infection suggests a potential for prophylactic use in humans," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. "We are moving as quickly as possible to test such a protective effect in patients at risk for COVID-19."
The paper can be accessed on the journal's website here.
https://www.nature.com/articles/s41586-020-2380-z
About Junshi Biosciences
Established in 2012, Junshi Biosciences is committed to developing first-in-class and best-in-class drugs through original innovation and becoming a pioneer in the area of translational medicine to provide patients with effective and affordable treatment options. On December 24, 2018, Junshi Biosciences was listed on the Main Board of the Stock Exchange of Hong Kong with the stock code: 1877.HK. The Company has established a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic diseases, autoimmune diseases, neurologic diseases, and Infectious disease. Product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai and Suzhou, Junshi has established the manufacturing infrastructure to support commercialization and provide our partners and patients with high-quality products through a global supply chain network. For more information, please visit:
http://junshipharma.com/en/Index.html
Contact Information
IR Team:
info@junshipharma.com
+ 86 021-2250 0300
Sectors: Daily Finance, Daily News, BioTech
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
More Latest Release >>